{"id":77821,"date":"2024-03-13T03:44:16","date_gmt":"2024-03-13T08:44:16","guid":{"rendered":"https:\/\/equitynewsreport.com\/jefferies-starts-cue-biopharma-stock-at-buy-on-il-2-platform-promise\/"},"modified":"2024-03-13T03:44:16","modified_gmt":"2024-03-13T08:44:16","slug":"jefferies-starts-cue-biopharma-stock-at-buy-on-il-2-platform-promise","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/jefferies-starts-cue-biopharma-stock-at-buy-on-il-2-platform-promise\/","title":{"rendered":"Jefferies starts Cue Biopharma stock at Buy on IL-2 platform promise"},"content":{"rendered":"<div readability=\"63\">\n<div id=\"imgCarousel\" class=\"imgCarousel\">\n<img decoding=\"async\" alt=\"Jefferies starts Cue Biopharma stock at Buy on IL-2 platform promise\" id=\"carouselImage\" src=\"https:\/\/i-invdn-com.investing.com\/news\/LYNXMPED0C0KP_L.jpg\"><br \/>\n<span class=\"text\">\u00a9 Reuters. <\/span><br \/>\n<i class=\"imgGrad\"><\/i>\n<\/div>\n<p>On Wednesday, the biotechnology company <span itemscope=\"\" itemtype=\"http:\/\/schema.org\/Corporation\"><span itemprop=\"name\"> Cue Biopharma <\/span><\/span> (NASDAQ:) saw its stock receive a favorable outlook from investment firm Jefferies, which initiated coverage with a Buy rating and a price target set at $6.00. The company&#8217;s innovative IL-2 platform, which aims to enhance the safety and efficacy over first-generation IL-2 therapies, was highlighted as a significant factor in this positive assessment.<\/p>\n<p>Cue Biopharma&#8217;s leading drug candidate, CUE-101, is currently under development for the treatment of HPV-positive head and neck squamous cell carcinoma (HNSCC) and has demonstrated promising preliminary results both as a monotherapy and in combination with pembrolizumab. The company has also achieved regulatory alignment following an End-of-Phase 1 meeting on the paths forward for this therapy.<\/p>\n<p>In addition to CUE-101, Cue Biopharma is working on CUE-102, targeting WT-1, which is in Phase I trials. The company&#8217;s pipeline also includes potential treatments for autoimmune diseases, further underscoring the potential of its platform. Jefferies sees the HNSCC opportunity as undervalued and suggests that a partnership this year could help address the company&#8217;s cash concerns and serve as a catalyst for the stock.<\/p>\n<p>Jefferies&#8217; coverage initiation reflects optimism about Cue Biopharma&#8217;s technology platform and its prospects in the market. The investment firm anticipates that the company&#8217;s novel approach and ongoing developments could lead to significant advancements in treatment options for cancer and autoimmune diseases.<\/p>\n<p><em>This article was generated with the support of AI and reviewed by an editor. For more information see our T&#038;C.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a9 Reuters. On Wednesday, the biotechnology company Cue Biopharma (NASDAQ:) saw its stock receive a favorable outlook from investment firm Jefferies, which initiated coverage with a Buy rating and a price target set at $6.00. The company&#8217;s innovative IL-2 platform, which aims to enhance the safety and efficacy over first-generation IL-2 therapies, was highlighted as a significant factor in this positive assessment. Cue Biopharma&#8217;s leading drug candidate, CUE-101, is currently under development for the treatment of HPV-positive head and neck squamous cell carcinoma (HNSCC) and has demonstrated promising preliminary results both as a monotherapy and in combination with pembrolizumab. The [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":77822,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,49,50,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77821"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77821"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77821\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77822"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}